1h Free Analyst Time
Speak directly to the analyst to clarify any post sales queries you may have.
1 of 4
FEATURED COMPANIES
- Amgen Inc.
- CSL Ltd.
- Horizon Therapeutics Plc
- Merck & Co., Inc.
- Novartis AG
- MORE
Immune thrombocytopenia is common among young women, and its risk is higher in people with diseases such as rheumatoid arthritis, HIV, hepatitis, lupus, and antiphospholipid syndrome. The prevalence of these diseases is high across the world. For instance, in 2016, over a million people in the US were diagnosed with HIV infection, and nearly 1% of the adults in the US had Hepatitis C. The growing incidences of such risk factors will increase the prevalence of immune thrombocytopenia. This will increase the demand for treatment options, thereby driving the growth of the global immune thrombocytopenia market size at a CAGR of nearly 5% during the forecast period.
Market Overview
Expected approvals for late-stage pipeline molecules
The market is witnessing accelerated growth in the number of molecules in the pipeline for the treatment of immune thrombocytopenia. At present, there are over 5 therapeutics to treat immune thrombocytopenia. These drugs are in the late stages of development and are slated to receive marketing approvals during the forecast period.
Availability of substitutes
The side effects associated with the available drugs for the treatment of immune thrombocytopenia are forcing healthcare practitioners to adopt alternative treatment options such as platelet transfusion and surgery. These treatment options have higher efficacies when compared to the available drugs. This is expected to pose a challenge to the growth of the global immune thrombocytopenia market size.
Competitive Landscape
The market appears to be fragmented with several players occupying the market share. Companies such as Amgen Inc. and CSL Ltd. Have intensified the competition. Factors such as the high prevalence of associated risk factors for immune thrombocytopenia and the expected approvals of late-stage pipeline molecules will provide significant growth opportunities for immune thrombocytopenia drug manufacturers. Amgen Inc., CSL Ltd., Horizon Therapeutics Plc, Merck & Co. Inc., Novartis AG, and Rigel Pharmaceuticals Inc. are some of the major companies covered in this report.
Market Overview
Expected approvals for late-stage pipeline molecules
The market is witnessing accelerated growth in the number of molecules in the pipeline for the treatment of immune thrombocytopenia. At present, there are over 5 therapeutics to treat immune thrombocytopenia. These drugs are in the late stages of development and are slated to receive marketing approvals during the forecast period.
Availability of substitutes
The side effects associated with the available drugs for the treatment of immune thrombocytopenia are forcing healthcare practitioners to adopt alternative treatment options such as platelet transfusion and surgery. These treatment options have higher efficacies when compared to the available drugs. This is expected to pose a challenge to the growth of the global immune thrombocytopenia market size.
Competitive Landscape
The market appears to be fragmented with several players occupying the market share. Companies such as Amgen Inc. and CSL Ltd. Have intensified the competition. Factors such as the high prevalence of associated risk factors for immune thrombocytopenia and the expected approvals of late-stage pipeline molecules will provide significant growth opportunities for immune thrombocytopenia drug manufacturers. Amgen Inc., CSL Ltd., Horizon Therapeutics Plc, Merck & Co. Inc., Novartis AG, and Rigel Pharmaceuticals Inc. are some of the major companies covered in this report.
Note: Product cover images may vary from those shown
2 of 4
FEATURED COMPANIES
- Amgen Inc.
- CSL Ltd.
- Horizon Therapeutics Plc
- Merck & Co., Inc.
- Novartis AG
- MORE
PART 01: EXECUTIVE SUMMARY
PART 02: SCOPE OF THE REPORT
PART 08: GEOGRAPHIC LANDSCAPE
PART 10: DRIVERS AND CHALLENGES
Exhibit 01: Global hematology drugs market
Exhibit 02: Segments of global hematology drugs market
Exhibit 03: Market characteristics
Exhibit 04: Market segments
Exhibit 05: Market definition - Inclusions and exclusions checklist
Exhibit 06: Market size 2018
Exhibit 07: Global market: Size and forecast 2018-2023 ($ millions)
Exhibit 08: Global market: Year-over-year growth 2019-2023 (%)
Exhibit 09: Five forces analysis 2018
Exhibit 10: Five forces analysis 2023
Exhibit 11: Bargaining power of buyers
Exhibit 12: Bargaining power of suppliers
Exhibit 13: Threat of new entrants
Exhibit 14: Threat of substitutes
Exhibit 15: Threat of rivalry
Exhibit 16: Market condition - Five forces 2018
Exhibit 17: Product - Market share 2018-2023 (%)
Exhibit 18: Comparison by product
Exhibit 19: TPO-RAs - Market size and forecast 2018-2023 ($ millions)
Exhibit 20: Approved TPO-RAs
Exhibit 21: Pipeline of TPO-RAs
Exhibit 22: TPO-RAs - Year-over-year growth 2019-2023 (%)
Exhibit 23: Corticosteroids - Market size and forecast 2018-2023 ($ millions)
Exhibit 24: Some of the generic sponsors for corticosteroids
Exhibit 25: Corticosteroids - Year-over-year growth 2019-2023 (%)
Exhibit 26: IVIGs - Market size and forecast 2018-2023 ($ millions)
Exhibit 27: Some of the available IVIGs
Exhibit 28: Side effects of IVIGs
Exhibit 29: Approximate Costs of IVIGs
Exhibit 30: IVIGs - Year-over-year growth 2019-2023 (%)
Exhibit 31: Other drugs - Market size and forecast 2018-2023 ($ millions)
Exhibit 32: Off-label drugs for immune thrombocytopenia
Exhibit 33: Other drugs - Year-over-year growth 2019-2023 (%)
Exhibit 34: Market opportunity by product
Exhibit 35: Customer landscape
Exhibit 36: Market share by geography 2018-2023 (%)
Exhibit 37: Geographic comparison
Exhibit 38: North America - Market size and forecast 2018-2023 ($ millions)
Exhibit 39: North America - Year-over-year growth 2019-2023 (%)
Exhibit 40: Top 3 countries in North America
Exhibit 41: Europe - Market size and forecast 2018-2023 ($ millions)
Exhibit 42: Europe - Year-over-year growth 2019-2023 (%)
Exhibit 43: Top 3 countries in Europe
Exhibit 44: Asia - Market size and forecast 2018-2023 ($ millions)
Exhibit 45: Asia - Year-over-year growth 2019-2023 (%)
Exhibit 46: Top 3 countries in Asia
Exhibit 47: ROW - Market size and forecast 2018-2023 ($ millions)
Exhibit 48: ROW - Year-over-year growth 2019-2023 (%)
Exhibit 49: Top 3 countries in ROW
Exhibit 50: Key leading countries
Exhibit 51: Market opportunity
Exhibit 52: Prevalence of associated risk factors for immune thrombocytopenia
Exhibit 53: Drug development pipeline for immune thrombocytopenia
Exhibit 54: Side effects associated with available drugs
Exhibit 55: Alternative therapies for immune thrombocytopenia
Exhibit 56: Impact of drivers and challenges
Exhibit 57: Drug designations
Exhibit 58: Vendor landscape
Exhibit 59: Landscape disruption
Exhibit 60: Vendors covered
Exhibit 61: Vendor classification
Exhibit 62: Market positioning of vendors
Exhibit 63: Amgen Inc. - Vendor overview
Exhibit 64: Amgen Inc. - Business segments
Exhibit 65: Amgen Inc. - Organizational developments
Exhibit 66: Amgen Inc. - Geographic focus
Exhibit 67: Amgen Inc. - Key offerings
Exhibit 68: Amgen Inc. - Key customers
Exhibit 69: CSL Ltd. - Vendor overview
Exhibit 70: CSL Ltd. - Business segments
Exhibit 71: CSL Ltd. - Organizational developments
Exhibit 72: CSL Ltd. - Geographic focus
Exhibit 73: CSL Ltd. - Segment focus
Exhibit 74: CSL Ltd. - Key offerings
Exhibit 75: CSL Ltd. - Key customers
Exhibit 76: Horizon Therapeutics Plc - Vendor overview
Exhibit 77: Horizon Therapeutics Plc - Business segments
Exhibit 78: Horizon Therapeutics Plc - Organizational developments
Exhibit 79: Horizon Therapeutics Plc - Geographic focus
Exhibit 80: Horizon Therapeutics Plc - Segment focus
Exhibit 81: Horizon Therapeutics Plc - Key offerings
Exhibit 82: Horizon Therapeutics Plc - Key customers
Exhibit 83: Merck & Co. Inc. - Vendor overview
Exhibit 84: Merck & Co. Inc. - Business segments
Exhibit 85: Merck & Co. Inc. - Organizational developments
Exhibit 86: Merck & Co. Inc. - Geographic focus
Exhibit 87: Merck & Co. Inc. - Segment focus
Exhibit 88: Merck & Co. Inc. - Key offerings
Exhibit 89: Merck & Co. Inc. - Key customers
Exhibit 90: Novartis AG - Vendor overview
Exhibit 91: Novartis AG - Business segments
Exhibit 92: Novartis AG - Organizational developments
Exhibit 93: Novartis AG - Geographic focus
Exhibit 94: Novartis AG - Segment focus
Exhibit 95: Novartis AG - Key offerings
Exhibit 96: Novartis AG - Key customers
Exhibit 97: Rigel Pharmaceuticals Inc. - Vendor overview
Exhibit 98: Rigel Pharmaceuticals Inc. - Business segments
Exhibit 99: Rigel Pharmaceuticals Inc. - Organizational developments
Exhibit 100: Rigel Pharmaceuticals Inc. - Key offerings
Exhibit 101: Rigel Pharmaceuticals Inc. - Key customers
Exhibit 102: Validation techniques employed for market sizing
Exhibit 103: Definition of market positioning of vendors
PART 02: SCOPE OF THE REPORT
- Preface
- Currency conversion rates for US$
- Market ecosystem
- Market characteristics
- Market segmentation analysis
- Market definition
- Market sizing 2018
- Market size and forecast 2018-2023
- Bargaining power of buyers
- Bargaining power of suppliers
- Threat of new entrants
- Threat of substitutes
- Threat of rivalry
- Market condition
- Market segmentation by product
- Comparison by product
- TPO-RAs - Market size and forecast 2018-2023
- Corticosteroids - Market size and forecast 2018-2023
- IVIGs - Market size and forecast 2018-2023
- Other drugs - Market size and forecast 2018-2023
- Market opportunity by product
PART 08: GEOGRAPHIC LANDSCAPE
- Geographic segmentation
- Geographic comparison
- North America - Market size and forecast 2018-2023
- Europe - Market size and forecast 2018-2023
- Asia - Market size and forecast 2018-2023
- ROW - Market size and forecast 2018-2023
- Key leading countries
- Market opportunity
PART 10: DRIVERS AND CHALLENGES
- Market drivers
- Market challenges
- Special regulatory designations
- Increasing number of awareness programs
- Development of biosimilars
- Overview
- Landscape disruption
- Competitive scenario
- Vendors covered
- Vendor classification
- Market positioning of vendors
- Amgen Inc.
- CSL Ltd.
- Horizon Therapeutics Plc
- Merck & Co., Inc.
- Novartis AG
- Rigel Pharmaceuticals Inc.
- Research methodology
- List of abbreviations
- Definition of market positioning of vendors
Exhibit 01: Global hematology drugs market
Exhibit 02: Segments of global hematology drugs market
Exhibit 03: Market characteristics
Exhibit 04: Market segments
Exhibit 05: Market definition - Inclusions and exclusions checklist
Exhibit 06: Market size 2018
Exhibit 07: Global market: Size and forecast 2018-2023 ($ millions)
Exhibit 08: Global market: Year-over-year growth 2019-2023 (%)
Exhibit 09: Five forces analysis 2018
Exhibit 10: Five forces analysis 2023
Exhibit 11: Bargaining power of buyers
Exhibit 12: Bargaining power of suppliers
Exhibit 13: Threat of new entrants
Exhibit 14: Threat of substitutes
Exhibit 15: Threat of rivalry
Exhibit 16: Market condition - Five forces 2018
Exhibit 17: Product - Market share 2018-2023 (%)
Exhibit 18: Comparison by product
Exhibit 19: TPO-RAs - Market size and forecast 2018-2023 ($ millions)
Exhibit 20: Approved TPO-RAs
Exhibit 21: Pipeline of TPO-RAs
Exhibit 22: TPO-RAs - Year-over-year growth 2019-2023 (%)
Exhibit 23: Corticosteroids - Market size and forecast 2018-2023 ($ millions)
Exhibit 24: Some of the generic sponsors for corticosteroids
Exhibit 25: Corticosteroids - Year-over-year growth 2019-2023 (%)
Exhibit 26: IVIGs - Market size and forecast 2018-2023 ($ millions)
Exhibit 27: Some of the available IVIGs
Exhibit 28: Side effects of IVIGs
Exhibit 29: Approximate Costs of IVIGs
Exhibit 30: IVIGs - Year-over-year growth 2019-2023 (%)
Exhibit 31: Other drugs - Market size and forecast 2018-2023 ($ millions)
Exhibit 32: Off-label drugs for immune thrombocytopenia
Exhibit 33: Other drugs - Year-over-year growth 2019-2023 (%)
Exhibit 34: Market opportunity by product
Exhibit 35: Customer landscape
Exhibit 36: Market share by geography 2018-2023 (%)
Exhibit 37: Geographic comparison
Exhibit 38: North America - Market size and forecast 2018-2023 ($ millions)
Exhibit 39: North America - Year-over-year growth 2019-2023 (%)
Exhibit 40: Top 3 countries in North America
Exhibit 41: Europe - Market size and forecast 2018-2023 ($ millions)
Exhibit 42: Europe - Year-over-year growth 2019-2023 (%)
Exhibit 43: Top 3 countries in Europe
Exhibit 44: Asia - Market size and forecast 2018-2023 ($ millions)
Exhibit 45: Asia - Year-over-year growth 2019-2023 (%)
Exhibit 46: Top 3 countries in Asia
Exhibit 47: ROW - Market size and forecast 2018-2023 ($ millions)
Exhibit 48: ROW - Year-over-year growth 2019-2023 (%)
Exhibit 49: Top 3 countries in ROW
Exhibit 50: Key leading countries
Exhibit 51: Market opportunity
Exhibit 52: Prevalence of associated risk factors for immune thrombocytopenia
Exhibit 53: Drug development pipeline for immune thrombocytopenia
Exhibit 54: Side effects associated with available drugs
Exhibit 55: Alternative therapies for immune thrombocytopenia
Exhibit 56: Impact of drivers and challenges
Exhibit 57: Drug designations
Exhibit 58: Vendor landscape
Exhibit 59: Landscape disruption
Exhibit 60: Vendors covered
Exhibit 61: Vendor classification
Exhibit 62: Market positioning of vendors
Exhibit 63: Amgen Inc. - Vendor overview
Exhibit 64: Amgen Inc. - Business segments
Exhibit 65: Amgen Inc. - Organizational developments
Exhibit 66: Amgen Inc. - Geographic focus
Exhibit 67: Amgen Inc. - Key offerings
Exhibit 68: Amgen Inc. - Key customers
Exhibit 69: CSL Ltd. - Vendor overview
Exhibit 70: CSL Ltd. - Business segments
Exhibit 71: CSL Ltd. - Organizational developments
Exhibit 72: CSL Ltd. - Geographic focus
Exhibit 73: CSL Ltd. - Segment focus
Exhibit 74: CSL Ltd. - Key offerings
Exhibit 75: CSL Ltd. - Key customers
Exhibit 76: Horizon Therapeutics Plc - Vendor overview
Exhibit 77: Horizon Therapeutics Plc - Business segments
Exhibit 78: Horizon Therapeutics Plc - Organizational developments
Exhibit 79: Horizon Therapeutics Plc - Geographic focus
Exhibit 80: Horizon Therapeutics Plc - Segment focus
Exhibit 81: Horizon Therapeutics Plc - Key offerings
Exhibit 82: Horizon Therapeutics Plc - Key customers
Exhibit 83: Merck & Co. Inc. - Vendor overview
Exhibit 84: Merck & Co. Inc. - Business segments
Exhibit 85: Merck & Co. Inc. - Organizational developments
Exhibit 86: Merck & Co. Inc. - Geographic focus
Exhibit 87: Merck & Co. Inc. - Segment focus
Exhibit 88: Merck & Co. Inc. - Key offerings
Exhibit 89: Merck & Co. Inc. - Key customers
Exhibit 90: Novartis AG - Vendor overview
Exhibit 91: Novartis AG - Business segments
Exhibit 92: Novartis AG - Organizational developments
Exhibit 93: Novartis AG - Geographic focus
Exhibit 94: Novartis AG - Segment focus
Exhibit 95: Novartis AG - Key offerings
Exhibit 96: Novartis AG - Key customers
Exhibit 97: Rigel Pharmaceuticals Inc. - Vendor overview
Exhibit 98: Rigel Pharmaceuticals Inc. - Business segments
Exhibit 99: Rigel Pharmaceuticals Inc. - Organizational developments
Exhibit 100: Rigel Pharmaceuticals Inc. - Key offerings
Exhibit 101: Rigel Pharmaceuticals Inc. - Key customers
Exhibit 102: Validation techniques employed for market sizing
Exhibit 103: Definition of market positioning of vendors
Note: Product cover images may vary from those shown
3 of 4
LOADING...
4 of 4
FEATURED COMPANIES
- Amgen Inc.
- CSL Ltd.
- Horizon Therapeutics Plc
- Merck & Co., Inc.
- Novartis AG
- MORE
The following companies are recognised as the key players in the global immune thrombocytopenia market: Amgen Inc., CSL Ltd., Horizon Therapeutics Plc, Merck & Co. Inc., Novartis AG, and Rigel Pharmaceuticals Inc.
Commenting on the report, an analyst from the research team said: “The latest trend gaining momentum in the market is the increasing number of awareness programs.”
According to the report, one of the major drivers for this market is the high prevalence associated risk factors for immune thrombocytopenia.
Further, the report states that one of the major factors hindering the growth of this market is the availability of substitutes.
The study was conducted using an objective combination of primary and secondary information, including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.
Commenting on the report, an analyst from the research team said: “The latest trend gaining momentum in the market is the increasing number of awareness programs.”
According to the report, one of the major drivers for this market is the high prevalence associated risk factors for immune thrombocytopenia.
Further, the report states that one of the major factors hindering the growth of this market is the availability of substitutes.
The study was conducted using an objective combination of primary and secondary information, including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.
Note: Product cover images may vary from those shown
5 of 4
- Amgen Inc.
- CSL Ltd.
- Horizon Therapeutics Plc
- Merck & Co., Inc.
- Novartis AG
- Rigel Pharmaceuticals Inc.
Note: Product cover images may vary from those shown
